{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Archer KJ"],"funding":["US National Cancer Institute","U.S. National Library of Medicine","Coleman Leukemia Research Foundation","NCI NIH HHS","American Society of Hematology","NLM NIH HHS","D. Warren Brown Family Foundation","Leukemia Research Foundation","Leukemia and Lymphoma Society"],"pagination":["28"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11068580"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk groups. Nevertheless, there remains heterogeneity with respect to relapse-free survival (RFS) within these genetic-risk groups. Our training set included 306 adults on Alliance for Clinical Trials in Oncology studies with de novo CN-AML aged < 60 years who achieved a complete remission and for whom centrally reviewed cytogenetics, RNA-sequencing, and gene mutation data from diagnostic samples were available (Alliance trial A152010). To overcome deficiencies of the Cox proportional hazards model when long-term survivors are present, we developed a penalized semi-parametric mixture cur"],"journal":["Journal of hematology & oncology"],"pubmed_title":["Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model."],"pmcid":["PMC11068580"],"funding_grant_id":["UG1CA233327","UG1CA233338","UG1 CA233339","U10CA180882","R35 CA197734","UG1 CA233327","R01 LM013879","UG1 CA233338","P30CA016058","R01LM013879","U10 CA180882","P30 CA016058","R01 CA283574","U24 CA196171","U24CA196171","U10 CA180821","UG1 CA233331"],"pubmed_authors":["Braess J","Spiekermann K","Uy GL","Herold T","Hiddemann W","Stock W","Mrozek K","Nicolet D","Mims AS","Metzeler KH","Archer KJ","Fu H","Byrd JC","Eisfeld AK"],"additional_accession":[]},"is_claimable":false,"name":"Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.","description":"Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk groups. Nevertheless, there remains heterogeneity with respect to relapse-free survival (RFS) within these genetic-risk groups. Our training set included 306 adults on Alliance for Clinical Trials in Oncology studies with de novo CN-AML aged < 60 years who achieved a complete remission and for whom centrally reviewed cytogenetics, RNA-sequencing, and gene mutation data from diagnostic samples were available (Alliance trial A152010). To overcome deficiencies of the Cox proportional hazards model when long-term survivors are present, we developed a penalized semi-parametric mixture cur","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-01T05:37:42.676Z","creation":"2026-04-08T09:41:11.373Z"},"accession":"S-EPMC11068580","cross_references":{"pubmed":["38702786"],"doi":["10.1186/s13045-024-01553-6"]}}